Preparation, characterization, and in vivo evaluation of tanshinone IIA solid dispersions with silica nanoparticles

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2285-2293

  Jiang, Yan Rong ^a,b   Zhang, Zhen Hai ^a   Liu, Qi Yuan ^a,b   Hu, Shao Ying ^a,b   Chen, Xiao Yun ^a,b   Jia, Xiao Bin ^a  

^a KEY LABORATORY OF NEW DRUG DELIVERY SYSTEM OF CHINESE MATERIA MEDICA   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

In vitro dissolution; Oral bioavailability; Silica nanoparticles; Solid dispersions; Stability; Tanshinone IIA

Indexed keywords

NANOPARTICLE; SILICON DIOXIDE; TANSHINONE IIA;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; SCANNING ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

IN VITRO DISSOLUTION; ORAL BIOAVAILABILITY; SILICA NANOPARTICLES; SOLID DISPERSIONS; STABILITY; TANSHINONE IIA;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DITERPENES, ABIETANE; DRUG CARRIERS; DRUG STABILITY; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; SILICON DIOXIDE; SOLUBILITY; SPECTRUM ANALYSIS;

EID: 84879559967     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40374     Document Type: Article

References (61)

1. Wang P, Wu X, Bao Y, etal. TSIIA prevents cardiac remodeling through attenuating NAD (P)H oxidase-derived reactive oxygen species production in hypertensive rats. Pharmazie. 2011;66(7):517-524.
2. Sun DD, Wang HC, Wang XB, etal. Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks) potassium channels. Eur J Pharmacol. 2008;590(1-3):317-321.
3. Gao J, Yang G, Pi R, etal. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res. 2008; 151(2):79-87.
4. Fu J, Huang H, Liu J, Pi R, Chen J, Liu P. TSIIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol. 2007;568(1-3):213-221.
5. Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med. 2006; 72(14):1311-1317.
6. Li J, Wang G, Li P, Hao H. Simultaneous determination of tanshinone IIA and cryptotanshinone in rat plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;826(1-2): 26-30.
7. Yu H, Subedi RK, Nepal PR, etal. Enhancement of solubility and dissolution rate of cryptotanshinone, tanshinone I and tanshinone IIA extracted from Salvia miltiorrhiza. Arch Pharm Res. 2012;35(8):1457-1464.
8. Yu XY, Lin SG, Zhou ZW, etal. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge. Curr Drug Metab. 2007;8(4):325-340.
9. Mao SJ, Hou SX, Liang Z, etal. Ion-pair reversed-phase HPLC: assay validation of sodium IIA sulfonate in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;831(1-2):163-168.
10. Wang L, Jiang X, Xu W, Li C. Complexation of tanshinone IIA with 2-hydroxypropyl-beta-cyclodextrin: effect on aqueous solubility, dissolution rate, and intestinal absorption behavior in rats. Int J Pharm. 2007;341(1-2):58-67.
11. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-1075.
12. Lennernäs H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol. 2005;57(3):273-285.
13. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60.
14. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol. 2006;6(5):501-508.
15. Tanaka N, Imai K, Okimoto K, etal. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation. J Control Release. 2006;112(1):51-56.
16. Shi F, Zhao JH, Liu Y, Wang Z, Zhang YT, Feng NP. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil. Int J Nanomedicine. 2012;7:2033-2043.
17. Kashanian S, Azandaryani AH, Derakhshandeh K. New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell. Int J Nanomedicine. 2011;6:2393-2401.
18. Li J, Liu P, Liu JP, Zhang WL, Yang JK, Fan YQ. Novel Tanshinone IIA ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2012;80(2):426-432.
19. Parmar Komal R, Satapara Vijay P, Shah Sunny R, Sheth Navin R. Improve-ment of dissolution properties of lamotrigine by inclusion complexation and solid dispersion technique. Pharmazie. 2011;66(2): 119-123.
20. Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine. 2011;6:2997-3009.
21. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system: New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50(1):3-12. 22. Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-309.
22. Bikiaris D, Papageorgiou GZ, Stergiou A, etal. Physicochemical studies on solid dispersions of poorly water-soluble drugs: evaluation of capabilities and limitations of thermal analysis techniques. Thermochim Acta. 2005;439(1-2):58-67.
23. He XQ, Pei LX, Tong HH, Zheng Y. Comparison of spray freeze drying and the solvent evaporation method for preparing solid dispersions of baicalein with Pluronic F68 to improve dissolution and oral bioavailability. AAPS Pharm Sci Tech. 2011;12(1):104-113.
24. Karavas E, Ktistis G, Xenakis A, Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur J Pharm Biopharm. 2006;63(2):103-114.
25. Pokharkar VB, Mandpe LP, Padamwar MN, Ambike AA, Mahadik KR, Paradkar A. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol. 2006;167(1):20-25.
26. Yang C, Xu X, Wang J, An Z. Use of the co-grinding method to enhance the dissolution behavior of a poorly water-soluble drug: generation of solvent-free drug-polymer solid dispersions. Chem Pharm Bull (Tokyo). 2012;60(7):837-845.
27. Kolašinac N, Kachrimanis K, Homšek I, Grujić B, Durić Z, Ibrić S. Solubility enhancement of desloratadine by solid dispersion in poloxamers. Int J Pharm. 2012;436(1-2):161-170.
28. Bley H, Fussnegger B, Bodmeier R. Characterization and stability of solid dispersions based on PEG/polymer blends. Int J Pharm. 2010;390(2):165-173.
29. Zhao X, Liu X, Gan L, Zhou C, Mo J. Preparation and physicochemical characterizations of tanshinone IIA solid dispersion. Arch Pharm Res. 2011;34(6):949-959.
30. Jondhale S, Bhise S, Pore Y. Physicochemical investigations and stability studies of amorphous gliclazide. AAPS Pharm Sci Tech. 2012;13(2):448-459.
31. Mellaerts R, Mols R, Jammaer JA, etal. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm. 2008;69(1):223-230.
32. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm. 2005;293(1-2):155-164.
33. Takeuchi H, Nagira S, Tanimura S, Yamamoto H, Kawashima Y. Tabletting of solid dispersion particles consisting of indomethacin and porous silica particles. Chem Pharm Bull (Tokyo). 2005;53(5):487-491.
34. Takeuchi H, Handa T, Kawashima Y. Spherical solid dispersion containing amorphous tolbutamide embedded in enteric coating polymers or colloidal silica prepared by spray-drying technique. Chem Pharm Bull (Tokyo). 1987;35(9):3800-3806.
35. Monkhouse DC, Lach JL. Use of adsorbents in enhancement of drug dissolution. II. J Pharm Sci. 1972;61(9):1435-1441.
36. Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur J Pharm Sci. 2005;26(2): 219-230.
37. Chen B, Wang Z, Quan G, etal. In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation. Int J Nanomedicine. 2012;7:199-209.
38. Du X, He J. Spherical silica micro/nanomaterials with hierarchical structures: synthesis and applications. Nanoscale. 2011;3(10): 3984-4002.
39. Cao X, Deng WW, Fu M, etal. In vitro release and in vitro-in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles. Int J Nanomedicine. 2012;7: 753-762.
40. Galagudza MM, Korolev DV, Sonin DL, etal. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. Int J Nanomedicine. 2010;5:231-237.
41. Corbalan JJ, Medina C, Jacoby A, Malinski T, Radomski MW. Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis. Int J Nanomedicine. 2012;7: 631-639.
42. Galagudza M, Korolev D, Postnov V, etal. Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles. Int J Nanomedicine. 2012;7:1671-1678.
43. Tho I, Liepold B, Rosenberg J, Maegerlein M, Brandl M, Fricker G. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. Eur J Pharm Sci. 2010;40(1):25-32.
44. Wang L, Cui FD, Sunada H. Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method. Chem Pharm Bull (Tokyo). 2006;54(1):37-43.
45. Yassin AE, Alanazi FK, El-Badry M, Alsarra IA, Barakat NS, Alanazi FK. Preparation and characterization of spironolactone-loaded gelucire microparticles using spray-drying technique. Drug Dev Ind Pharm. 2009;35(3):297-304.
46. Van Eerdenbrugh B, Van Speybroeck M, Mols R, etal. Itraconazole/TPGS/Aerosil200solid dispersions: characterization, physical stability and in vivo performance. Eur J Pharm Sci. 2009;38(3):270-278.
47. Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine. 2011;6:2997-3009.
48. Guedes FL, de Oliveira BG, Hernandes MZ, etal. Solid dispersions of imidazolidinedione by PEG and PVP polymers with potential antischistosomal activities. AAPS Pharm Sci Tech. 2011;12(1): 401-410.
49. Jondhale S, Bhise S, Pore Y. Physicochemical investigations and stability studies of amorphous gliclazide. AAPS Pharm Sci Tech. 2012;13(2):448-459.
50. Vippagunta SR, Maul KA, Tallavajhala S, Grant DJ. Solid state characterization of nifedipine solid dispersions. Int J Pharm. 2002; 236(1-2):111-123.
51. Kawabata Y, Yamamoto K, Debari K, Onoue S, Yamada S. Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur J Pharm Sci. 2010;39(4): 256-262.
52. Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-309.
53. Li J, Liu P, Liu JP, Zhang WL, Yang JK, Fan YQ. Novel Tanshinone IIA ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2012;80(2):426-432.
54. Wang L, Lu A, Wang C, Zheng X, Zhao D, Liu R. Nano-fibriform production of silica from natural chrysotile. J Colloid Interface Sci. 2006;295(2):436-439.
55. Planinšek O, Kovačič B, Vrečer F. Carvedilol dissolution improvement by preparation of solid dispersions with porous silica. Int J Pharm. 2011;406(1-2):41-48.
56. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60.
57. Hu KL, Cao S, Hu FQ, Feng JF. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. Int J Nanomedicine. 2012;7:3537-3545.
58. Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12): 1504-1534.
59. Falahati M, Saboury AA, Ma'mani L, Shafiee A, Rafieepour HA. The effect of functionalization of mesoporous silica nanoparticles on the interaction and stability of confined enzyme. Int J Biol Macromol. 2012;50(4):1048-1054.
60. Galagudza M, Korolev D, Postnov V, etal. Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles. Int J Nanomedicine. 2012;7:1671-1678.
61. Cheang TY, Tang B, Xu AW, et al. Promising plasmid DNA vector based on APTES-modified silica nanoparticles. Int J Nanomedicine. 2012;7:1061-1067.